SHAREHOLDER ALERT: Kiromic Biopharma, Inc. (KRBP) Officers and Directors Under Investigation for Possible False Statements About Its Commercial Prospects

Provided By PR Newswire

Last update: Nov 8, 2022

SAN FRANCISCO, Nov. 8, 2022 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Kiromic Biopharma, Inc. (NASDAQ: KRBP) relating to possible false and misleading statements to investors concerning commercial prospects for the company's immunotherapy medications.